Woodline Partners »

Rapport Therapeutics shares owned by Woodline Partners

Quarter-by-quarter ownership of Rapport Therapeutics shares owned by Woodline Partners from 13F filings

Historical chart of Woodline Partners investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Woodline Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Woodline Partners

Quarter filed Position value Share count Share price at filing
2024-06-30 $4.0M 171k 23.26

More positions owned by Woodline Partners

Eli Lilly & Co. (LLY)
Regeneron Pharmaceuticals (REGN)
Encana Corporation (OVV)
Te Connectivity SHS (TEL)
Abbvie (ABBV)
Revolution Medicines (RVMD)
Chord Energy Corporation Com New (CHRD)
Meta Platforms Cl A (META)
Marsh & McLennan Companies (MMC)
Permian Resources Corp Class A Com (PR)
Quest Diagnostics Incorporated (DGX)
Civitas Resources Com New (CIVI)
Electronic Arts (EA)
Progressive Corporation (PGR)
Zimmer Holdings (ZBH)

View all positions for Woodline Partners

Top funds holding Rapport Therapeutics

Arch Venture Corp
Cormorant Asset Management
Johnson & Johnson
Sofinnova Ventures
T. Rowe Price Investment Management
T. Rowe Price Associates
Alliancebernstein
Perceptive Advisors
Citadel Advisors
Artal Group
Logos Global Management
Woodline Partners
Millennium Management
TD Asset Management
Manufacturers Life Insurance Company

View all funds holding Rapport Therapeutics